Intellia Therapeutics (NTLA) Q2 2026 Earnings

Yes. Intellia Therapeutics reported Q2 2026 earnings of $-0.80 a share on Aug 6, 2026, beating the $-0.90 consensus estimate by 10.9%. Revenue was $7.7M against a $13.0M estimate.

Intellia Therapeutics delivered a mixed second quarter for 2026, missing on both the top and bottom lines even as a landmark clinical readout underscored the promise of its gene editing platform. The company posted a GAAP net loss of $0.80 per share, falling short of the $0.78 consensus by 1.95%, snapping a streak of six consecutive quarterly EPS beats. Collaboration revenue tumbled 46.2% year over year to $7.66 million, coming in well below the $12.98 million analysts had expected, as reduced contributions from Regeneron on the nex-z program weighed heavily on the top line. The headline story, however, was the Phase 3 HAELO trial for lonvoguran ziclumeran in hereditary angioedema, which demonstrated an 87% reduction in attacks versus placebo and was published in the New England Journal of Medicine. G&A expenses climbed to $37.82 million from $27.21 million a year ago, reflecting aggressive commercial buildout ahead of a planned U.S. launch in the first half of 2027, contingent on BLA acceptance expected later this year. Intellia ended the quarter with $628.35 million in cash, providing runway into at least 2028.